Remove Access Remove DEA Remove History Remove Policy
article thumbnail

Court Dismisses Case Demanding DEA to Move Expeditiously to License Cannabis Cultivators

NORML

Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.

DEA 104
article thumbnail

DEA Finally Agrees to Expand Marijuana Research Amid Pressure from Lawsuit

WeedAdvisor

Despite a 90-day deadline for review, the DEA ignored this cut-off and simply sat on the applications for three years. This likely would have been longer, but the DEA had not anticipated a legal threat to force some action. Given the DEA’s stonewalling, forcing their hand is a notable achievement. Dozens of Applications”. .

DEA 61
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Medical Marijuana and Cannabidiol Research Expansion Act Has Passed

Veriheal

This makes history by enacting the first piece of standalone federal cannabis reform legislation in U.S. The Drug Enforcement Administration (DEA) is now mandated to approve applications to be manufacturers of marijuana-derived, FDA-approved drugs under the bill. The law gives the U.S. The law gives the U.S. Descheduling Cannabis.

article thumbnail

American Bar Association Urges Congress To Let States Set Their Own Marijuana Policies

SMPL

The American Bar Association (ABA) adopted a resolution on Monday that calls on Congress to allow states to set their own marijuana policies and recommends rescheduling or descheduling cannabis under federal law. One area that could be quickly improved is in the sourcing of research-grade marijuana.

Policy 40
article thumbnail

The Path to Greenlighting CBD

Burns Levinson (Cannabusiness advisory)

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval. Therefore, it no longer meets the criteria for placement in Schedule I.

CBD 40
article thumbnail

Q&A with Mason Marks on New Psychedelics Law and Regulation Initiative @ Harvard

Cannabis Law Report

The Project on Psychedelics Law and Regulation at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School will advance evidence-based psychedelics law and policy. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries.

Law 105
article thumbnail

Daniella Styagova: United States v. Oakland Cannabis Buyers’ Cooperative

Cannabis Law Report

Facts and Procedural History: The Controlled Substances Act was passed in 1970 and created a single legal framework for regulating substances that are thought to have a high risk of abuse and addiction. To consider the full impact of this Supreme Court decision it is necessary to delve into the history of the Controlled Substance Act.

DEA 52